Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qilu Pharmaceutical Co., Ltd.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male or female subjects, ages 18-65 inclusive, with a clinical diagnosis of schizophrenia
PANSS total score ≥ 70 and ≤ 120，Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behavior, conceptual disorganization, and unusual thought content
CGI-S score ≥ 4
You may not be if
Currently, meet DSM-5 diagnostic criteria for other psychiatric disorders ( for example schizoaffective disorder, schizophreniform disorder, bipolar I and II disorder; pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders；
known or suspected borderline or antisocial personality disorder or other psychiatric disorders of sufficient severity to interfere with participation in the study
Clareo Health | Study on the Efficacy and Safety of QLM1016 in Schizophrenia
